Advances in the Role of Low-Dose Interleukin-2 in Immune-Mediated Dermatosis.
10.3881/j.issn.1000-503X.15198
- Author:
Zu-Sha QIAO
1
;
Hong-Zhong JIN
2
Author Information
1. Department of Dermatology,Second Hospital of Shanxi Medical University,Taiyuan 030001,China.
2. Department of Dermatology,PUMC Hospital,CAMS and PUMC,Beijing 100730,China.
- Publication Type:Journal Article
- Keywords:
effector T cell;
immune-mediated dermatosis;
interleukin-2;
regulatory T cell
- MeSH:
Humans;
Interleukin-2;
Lupus Erythematosus, Systemic;
T-Lymphocytes, Regulatory;
Skin Diseases/drug therapy*
- From:
Acta Academiae Medicinae Sinicae
2023;45(4):683-688
- CountryChina
- Language:Chinese
-
Abstract:
Immune-mediated dermatoses are the skin diseases caused by the breakdown of immune tolerance,including lupus erythematosus and dermatomyositis.The imbalance between regulatory T cells (Tregs) and effector T cells (Teffs) plays a key role in the pathogenesis of these diseases.Low-dose interleukin-2 can preferentially activate Tregs and reverse the imbalance between Tregs and Teffs to recover the immune tolerance,which has attracted attention in the treatment of immune-mediated dermatoses.This review summarizes the research progress in the immunomodulatory mechanism and clinical application of low-dose interleukin-2 in immune-mediated dermatoses,providing a new idea for the clinical treatment of these diseases.
